Shots:
- Everest to get the rights to develop & commercialize Abs resulting from the collaboration. AbCellera to receive research payments and is eligible to receive clinical and commercial milestones along with royalties on net sales of products
- The collaboration will accelerate Everest’s portfolio to discover novel medicines for up to 10 targets across multiple indications by utilizing AbCellera’s AI technology
- Everest gets a benefit from an operating system that helps to supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access
Click here to read full press release/ article | Ref: Businesswire | Image: AbCellera
The post AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies first appeared on PharmaShots.
